PMID- 8495983
OWN - NLM
STAT- MEDLINE
DCOM- 19930624
LR  - 20130418
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 98
DP  - 1993 Feb
TI  - Emerging concepts in the management of acute lymphoblastic leukaemia.
PG  - 1-7
AB  - Modern chemotherapy can cure more than 70 per cent of children with standard risk 
      acute lymphoblastic leukaemia (ALL). Encouraging results are also reported in 
      children with high risk ALL receiving intensive chemotherapy. Results in adults 
      with ALL are less satisfactory, the long term survival is less than 35 per cent. 
      Further dose intensification as possible in the setting of bone marrow 
      transplantation (BMT) has increased the cure rate to 50 per cent in adult ALL. 
      Allogeneic BMT has, however, besides the enhanced antileukaemia activity related 
      to high dose therapy, additional antileukaemia effect related to immune 
      mechanisms. Immune effects may be separated into three elements viz., an 
      antileukaemia effect of graft vs host disease (GvHD), a separate antileukaemia 
      effect of T cells and possibly a specific graft vs leukemia effect (GvL). These 
      immune mediated antileukaemic effects offer a new potential therapeutic modality. 
      For instance, the T cell antileukaemic effect of transplant could be achieved by 
      transfusing radiated T cells or administering lymphokines. Alternatively 
      autologous bone marrow could be manipulated in vitro prior to reinfusion. 
      Manipulation might include activation of natural killer (NK) cells or lymphokine 
      activated killer (LAK) activity. Another newer approach to treat ALL is the use 
      of hemopoietic growth factors. Use of these factors prior to chemotherapy may 
      increase the proportion of proliferating leukaemic stem cells. This would 
      increase the efficacy of many drugs since most are active against proliferating 
      cells. Hemopoietic regulatory factors could also be used to directly inhibit 
      leukemic cell growth or to promote differentiation.(ABSTRACT TRUNCATED AT 250 
      WORDS)
FAU - Kochupillai, V
AU  - Kochupillai V
AD  - Department of Medical Oncology, Institute Rotary Cancer Hospital, All India 
      Institute of Medical Sciences, New Delhi.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Hematopoietic Cell Growth Factors)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Marrow Transplantation
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Hematopoietic Cell Growth Factors/therapeutic use
MH  - Humans
MH  - Immunotherapy
MH  - Infant
MH  - Male
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
MH  - Prognosis
MH  - Remission Induction
MH  - Risk Factors
RF  - 42
EDAT- 1993/02/01 00:00
MHDA- 1993/02/01 00:01
CRDT- 1993/02/01 00:00
PHST- 1993/02/01 00:00 [pubmed]
PHST- 1993/02/01 00:01 [medline]
PHST- 1993/02/01 00:00 [entrez]
PST - ppublish
SO  - Indian J Med Res. 1993 Feb;98:1-7.